Solid Biosciences

ABV-202 Clin0 Friedreich's ataxia; AVB-401 Clin0 dilated cardiomyopathy; undisclosed Clin0 cardiac condition

Solid Biosciences is advancing genetic medicines to treat patients with neuromuscular and cardiac diseases. To create effective therapies, Solid has built a state-of-the-art process development and characterization lab to establish their transient transfection-based gene therapies. Solid’s pipeline includes SGT-003, a treatment for Duchenne muscular dystrophy and AVB-401, a treatment for BAG3-mediated dilated cardiomyopathy. As the programs progress, Solid will continue to refine their manufacturing process so that they can meet their goal of ensuring that no patient goes without therapy.